Esomeprazole Mg
ApprovedSmall molecule
AstraZenecaEsomeprazole Mg is one of 143 small molecule programs targeting Esophageal Cancer. It is currently in Approved.
5
Indications
15
Total Trials
0
Active Trials
142
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
341 competitors in Esophageal Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Eloxatin
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Keytruda
Merck & Co.Phase 3
Adrucil
EElorac, Inc.
Phase 3
Camptosar
PfizerPhase 3
Taxotere
AAvyxa
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gastroesophageal Reflux Disease2 trials
MPA1 trial
Critically Ill1 trial
Reflux1 trial
9 more indications
Esophageal Cancer1 trial
Upper Gastrointestinal Bleeding1 trial
Zollinger-Ellison Syndrome1 trial
Concentration1 trial
Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers
Completed·—·Phase 1·NCT01135472·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Esomeprazole Mg. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company